Co-Diagnostics, Inc.

CODX Healthcare Medical Devices

Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.

0.65 0.07 −9.72%
Market cap
$5.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
2/9
Altman Z
−9.74
Beneish M
2.24
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
25.64 10.83 5.84 18.52
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(2.21) (1.09) (0.53) (1.87)
P/B ratio
0.33 0.33 0.26 1.05
EV/Sales
3.11 (8.26) (5.62) 13.46
EV/EBITDA
0.00 0.10 0.08 0.00
EV/FCF
(0.05) 0.17 0.14 (0.35)
Current Ratio
3.81 3.87 2.28 1.81
Net Debt/EBITDA
1.70 0.45 0.92 0.61
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(288.08%) (699.25%) (1,736.83%) (866.39%)
Free Cash Flow Yield
(244.28%) (442.41%) (691.59%) (205.60%)
Free Cash Flow per Share
(4.74) (4.76) (3.54) (1.66)
Book value per Share
31.56 15.51 7.12 2.95
Free Cash Flow
(5.98) (6.33) (7.99) (7.17)
EV/EBIT
0.00 0.10 0.08 0.00
Other line items

Show all line items

Columns are period end dates